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own tissues; in this light, it is interesting to
consider that the gene encoding Foxp3
appeared early in vertebrate evolution
and is present in all jawed vertebrates,
with the possible exception of birds.
Interestingly, the coding sequence of
Foxp3 became highly conserved in eu-
therian mammals (Andersen et al., 2012).
Thus, several transposable elements
acted as building blocks in the evolu-
tion of eutherian mammals, Mer20,
RAG1/2, andCNS1, eachonecontributing
to the evolutionary fitness of placental
animals.
The findings by Samstein et al. provide
unique insight into the evolution of mam-mals. The study raises questions about
the TGFb dependence of pTreg in noneu-
therian mammals and other Foxp3-
expressing vertebrates. Finally, it raises
the possibility that defects in the genera-
tion of pTreg may be at the root of condi-
tions such as pre-eclampsia.REFERENCES
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Expression of eukaryotic mRNAs requires the collaboration of a host of RNA processing factors
acting upon the transcript. Berg et al. describe how a pre-mRNA splicing factor modulates the
activity of the polyadenylation machinery to regulate mRNA length, with important implications
for isoform expression in activated neuronal and immune cells.Formation of messenger RNAs (mRNAs)
from pre-mRNA transcripts involves
multiple processing steps, including 50
end capping, intron removal via pre-
mRNA splicing, and 30 end cleavage/poly-
adenylation. Although these processes
have been studied as biochemically
distinct reactions, they each appear to
occur cotranscriptionally and in close
spatial and temporal proximity to one
another, raising important questions
about how they may act coordinately to
affect gene expression outcomes. One
of these cotranscriptional processes, pol-
yadenylation, can occur at multiple sites
in more than half of mammalian tran-
scripts (Tian et al., 2005), and genome-
wide surveys of poly(A) RNA have recently
demonstrated that 30 cleavage and polya-
denylation may occur throughout a pre-
mRNA (Kaida et al., 2010; Weill et al.,2012). In this issue, Berg and colleagues
demonstrate that U1 small nuclear RNA
(snRNA), an RNA typically associated
with splicing, regulates transcript length
through cotranscriptional recognition of
cryptic polyadenylation signals (PASs)
and inhibition of premature cleavage and
polyadenylation (PCPA) at these sites
(Figure 1) (Berg et al., 2012). This process,
which the authors term ‘‘telescripting,’’
appears to make functional contributions
to transcriptional control of activated neu-
ronal cells.
U1 snRNA is best characterized for its
role in recognizing the 50 splice site (50ss)
during removal of introns from pre-
mRNAs; however, it is present at levels
far exceeding what is necessary for pre-
mRNA splicing in the cell (Baserga and
Steitz, 1993), and it is the only snRNA
that localizes to intronless genes (Brodyet al., 2011). Additionally, the splicing-
associated U1 small nuclear ribonu-
cleoprotein (snRNP) particle inhibits
pre-mRNA polyadenylation through its
interaction with poly(A) polymerase (Gun-
derson et al., 1994, 1998). U1 snRNA
has also been implicated in a splicing-
independent role in transcriptional activa-
tion (Kwek et al., 2002), and the Dreyfuss
lab previously described a role for U1 in
protecting pre-mRNAs from cleavage
and polyadenylation (Kaida et al., 2010).
Although integral to pre-mRNA splicing,
these observations point to nonsplicing
functions for the U1 snRNA and perhaps
its associated proteins.
The Kaida et al. (2010) study described
above found that U1 snRNA bound to
cryptic 50ss within the mRNA protected
internal PASs from premature process-
ing. To look more closely at how U1ell 150, July 6, 2012 ª2012 Elsevier Inc. 9
Figure 1. U1 Levels Determine the Use of Premature Cleavage and Polyadenylation Sites
(A) At wild-type levels of U1, U1 snRNA base pairing at the 50ss inhibits the use of proximal PASs, leading to generation of a full-length transcript polyadenylated at
the 30 end. Potential cleavage sites far downstreamof the 50ss are also inhibited by the activity of U1, presumably via 50ss-independent interactions (or perhaps by
recognition of cryptic 50ss signals).
(B) When U1 snRNA is depleted experimentally, as with AMO, it is not available to splice pre-mRNAs or to inhibit the use of PASs in the first intron, and as
a consequence, short cleaved and polyadenylated RNAs are generated through PCPA.
(C) When U1 snRNA is decreased experimentally (by titrating AMO levels), the 30 end of the RNA becomes shorter due to a decrease in U1-mediated protection
from PCPA. A greater decrease in U1 snRNA levels leads to usage of cryptic PASs closer to the 50 end of the RNA.
(D) 30 UTR shortening and 30 exon switching have been observed in activated neuronal and immune cells to produce shortened transcripts similar to the observed
effects of decreasing U1 levels. Rapid and transient transcriptional upregulation of pre-mRNAs creates a shortage of U1 snRNA relative to the amount of nascent
pre-mRNA, leading to the production of short isoforms under activated conditions (For example, homer-1 long is produced in unactivated neuronal cells, whereas
homer-1 short predominates in activated cells). It is unclear whether other, perhaps unstable, isoforms are also produced.
For each panel, RNA polymerase II is shown synthesizing PAS-containing pre-mRNA from a chromatin template. The pre-mRNA is shown with exons (colored
boxes), introns, the 50 cap (red ball), and multiple PAS sequences. The purple ovals represent components of the polyadenylation machinery that associate with
the C-terminal domain (CTD) of RNA polymerase II. The U1 snRNA is depicted in association with spliceosomal proteins (light blue ovals).influences pre-mRNA cleavage/polyade-
nylation, Berg et al. (2012) now use
antisense morpholino oligonucleotides
(AMO) to knock down U1 snRNA expres-
sion and genome-wide high-throughput
sequencing of differentially expressed
transcripts (HIDE-seq) to identify global
poly(A) transcripts. Looking at expression
patterns in a number of organisms, this
analysis confirms that U1 snRNA protects
transcripts from premature cleavage and
polyadenylation.10 Cell 150, July 6, 2012 ª2012 Elsevier Inc.To then address whether a 50ss
sequence is necessary and sufficient for
PCPA, the authors utilize minigenes with
‘‘actionable’’ polyadenylation sequences
and find that PCPA occurs at a proximal
PAS when the 50ss has been mutated—
that is, when U1 cannot bind. However,
if the 50ss-proximal PAS is also mutated,
a PAS sequence further downstream
from the 50ss is used. Intriguingly, even
in this context of a mutated 50ss that is
unable to support U1 snRNA binding, U1snRNA knockdown exacerbates use of
the downstream PAS, indicating that
PCPA suppression is conferred by U1
interactions outside the 50ss and suggest-
ing a 50 to 30 directionality to U1 protec-
tion from PCPA. The authors see similar
directional effects and shortened mRNAs
when they titrate the amount of AMO to
progressively inhibit U1 snRNA, which is
consistent with U1 ‘‘telescripting’’ acting
in a 50 to 30 direction, mirroring RNA syn-
thesis. Berg and colleagues also observe
that changes in U1 can alter alternative
splicing by an unexpected mechanism;
namely, PCPA-dependent changes in
poly(A) sites trigger 30 exon switching.
This suggests that there may be a
splicing-independent role for U1 in regu-
lation of alternative splicing.
An important question raised by these
studies is that, as U1 snRNA levels are
high and remain relatively constant in
the cell, how can they change enough
under physiological conditions to modu-
late PCPA? The authors propose a model
whereby cells undergoing rapid activa-
tion, e.g., activated neuronal and immune
cells, experience a transient but dramatic
increase in the transcript to U1 snRNA
ratio due to an increase in transcription.
In this case, the comparative decrease in
the available U1 would be predicted to
lead to PCPA and mRNA shortening.
Indeed, the authors see a 40%–50%
increase in nascent pre-mRNA transcripts
in activated neurons and show that
shorter mRNAs result. Importantly, they
demonstrate that shortening of specific
transcripts can be overcome by U1 over-
expression. These changes to themRNAs
can result in shifts in protein isoform
abundance (for instance, Homer-1 long
and short isoforms) that may serve dis-
tinct functional roles in activated neurons.
In addition to creating different protein
isoforms, changes to the 30 end of tran-
scripts by alternative polyadenylation
site usage have the potential to alter
cellular amounts of these transcripts.
‘‘Telescripting’’ may lead to a change in
transcript levels due to loss of binding
sites for miRNAs (or other RNA stability
elements) in the 30 untranslated region
(UTR). The extent to which the available
30 UTR regulatory sequences are altered
by PCPA remains to be explored.It appears that signals outside of known
50ss contribute to U1 suppression of
PCPA. Most simply, U1 binding to unan-
notated cryptic 50ss may be involved.
However, it is also possible that signals
in chromatin, such as histone modifi-
cations or nucleosome occupancy, or
changes in the elongation properties of
polymerase may facilitate U1 snRNA
localization to the nascent transcript.
Several recent studies from yeast to
mammals support a role for chromatin
in cotranscriptional splicing factor locali-
zation and rearrangements (see, for
example, Gunderson et al., 2011). Identifi-
cation of genome-wide binding sites for
the U1 snRNP by using high-throughput
analyses will be extremely informative
for identifying these signals, particularly
under conditions in which U1 snRNA
becomes limiting, such as in neuronal
activation, and will ultimately help eluci-
date the mechanism by which the U1
snRNP influences transcript length.
Finally, what is the outcome of tran-
script length changes in response to
PCPA? One might imagine that, under
conditions in which rapid proteome
expansion is necessary, such as during
immune activation or perhaps during de-
velopment, U1 snRNA-modulated PCPA
might produce new transcripts with
new biological functions, thus increasing
proteome diversity upon translation. Con-
versely, in diseases of transcriptional
dysregulation, such as many types of
cancers, it will be important to determine
whether increased mRNA transcription
leads to truncated transcripts generated
by PCPA and concomitant production of
truncated proteins with roles in patho-
genesis. The use of powerful, validated
high-throughput tools, such as HIDE-
seq, to help enrich the discovery andCidentification of these transcripts and their
respective proteins will aid in our under-
standing of how cotranscriptional cross-
talk between RNA processing factors
leads to coordinated regulation of gene
expression.ACKNOWLEDGMENTS
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